Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs 22nd Century Group Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.35 (market cap $142.30B), while 22nd Century Group Inc trades at $4.27 (market cap $1.45M). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 98137.9× 22nd Century Group Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| BBVA | XXII | |
|---|---|---|
Market Cap | $142.30B | $1.45M |
Sector | Financials | Technology |
52-Week High | $26.14 | $1.47K |
52-Week Low | $14.73 | $3.90 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | -$6.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
XXII trades at $4.10, down 3.07% today, with a bearish technical signal from moving averages. The company shows severe financial distress with a negative gross profit margin of -52.19% and net income margin of -65.76% for 2025. Recent news highlights expansion of VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. A 20:1 reverse stock split occurred on June 12, 2026, to adjust share structure.
The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is 75% buy-rated. Investment opportunity hinges on successful commercialization of VLN products and FDA regulatory renewals. Key risks include execution challenges, intense competition, and reliance on financing to sustain operations amid negative cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
